Skip to content
BOLUS

Signal from the log

Link Cell Therapies

30 M$ · Series A · United States · Biotech

Link Cell Therapies développe des CAR-T à porte logique, qui n'attaquent une cellule que si elle porte deux cibles à la fois, pour viser les tumeurs solides sans détruire les tissus sains. Son premier produit, LNK001, entre en phase 1 à MD Anderson dans le cancer du rein à cellules claires. La série A menée par Johnson & Johnson Innovation, JJDC passe de 60 à 90 M$.

Article

Announced on , logged by the watch of 28 September 2026.

Operation
Funding round
Announced amount
30 M$
Stage
Series A
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Sujet traité. L'article donne les sources et la position de Bolus.

The investors

Led by Johnson & Johnson Innovation, JJDC , with Samsara BioCapital , Sheatree Capital , Wing Venture Capital , Bristol Myers Squibb , Kyowa Kirin , Sherpa Healthcare Partners , Western Technology Investment , MD Anderson Cancer Focus Fund

Read the article on this operation (in French)

Provenance
Source prnewswire
Logged on 28 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

You are, if you care to say

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).